Stocks to sell

The stock market has gotten volatile lately. Shares dropped sharply in recent days on worries around the renewed spread of Covid-19 and its Delta variant. However, stocks rapidly rebounded as investors went bargain-hunting, particularly in Covid-impacted stocks. In any case, the stock market indexes remain fairly near their all-time highs. This makes it a good

When it comes to stocks, I tend to be a glass-half-full kind of person, which is why I don’t often write about stocks to sell.  Alas, you can run, but you can’t hide. So I’ve been asked to come up with 10 names I feel investors ought to jettison before they crash and burn.  What

Based on my financial analysis, I would not touch Bionano Genomics (NASDAQ:BNGO) right now. I would run fast and far away from BNGO stock. But why? There are several reasons, and they all have to do with fundamentals. Source: Natali_ Mis/ShutterStock.com While the company has a positive catalyst here and there, its revenue and subsequent

Health insurance company Clover Health (NASDAQ:CLOV) is on a mission to lower costs for Medicare patients. So far, it is spending more money than it brings in. Additionally, activist short-seller Hindenburg Research released a scathing report that criticizes its business model and the quality of its software. As a result, CLOV stock is incredibly volatile

Many may be waiting for the other shoe to drop with Gamestop (NYSE:GME) stock. But not even market-wide jitters about the Delta variant could knock down the most popular “meme stock.” In fact, on the day the Dow slumped over concerns, GME stock ticked higher rather than lower. Source: Emil O / Shutterstock.com Will this

AMC (NYSE:AMC) announced the appointment of CEO Adam Aron to the additional position of Chairman of the Board on July 21. Before you run out to buy AMC stock on the news, you might want to do a stress test on America’s largest movie theater chain.  Source: Sundry Photography / Shutterstock.com You might not like

In the rosiest of scenarios for Ocugen (NASDAQ:OCGN) stock, the Covaxin vaccine for the novel coronavirus will be approved by the FDA only around the second quarter of 2023. And the company appears to be dragging its feet on getting the process started. Source: shutterstock.com/PhotobyTawat Meanwhile, information I recently uncovered suggests that Canada will probably

Is healthcare insurer Clover Health Investments (NASDAQ:CLOV) stock more than a meme play? Source: Valeri Potapova / Shutterstock.com This is the fundamental question that both professional and retail investors are trying to answer after CLOV stock was targeted in late May by the meme stock crowd that congregates on the WallStreetBets Reddit forum. The share

When I last wrote about Fisker (NYSE:FSR) stock in April, I said I liked the stock better when it was trading near $13 a share. Source: T. Schneider / Shutterstock.com It seems at least some investors agreed that they preferred an even lower entry point. FSR  stock dropped below the $10 mark in late May.   But

AMC Entertainment (NYSE:AMC) stock, even with its recent troubles, is still up approximately 1,500% year-to-date. Source: Sundry Photography / Shutterstock.com When meme stock mania kicked off in January, many Wall Street analysts expected it to blow over quickly, but it hasn’t. Indeed, leading meme names such as GameStop (NYSE:GME) and AMC remain at sharply higher

Clover Health Investments (NASDAQ:CLOV) recently reported Q1 revenue and earnings on May 17. The numbers weren’t particularly thrilling for CLOV stockholders. Source: Valeri Potapova / Shutterstock.com On May 13 I wrote that the Medicare Advantage insurer would likely report 21% higher revenue year-over-year. But I also cautioned that CLOV stock was unlikely to move much

In any other circumstance, Opendoor Technologies (NASDAQ:OPEN) stock may have been a no-brainer investment. Source: PREMIO STOCK/Shutterstock.com As you probably know, owning real estate is the epitome of the American Dream — but the paperwork to seal the deal is a veritable nightmare. Opendoor’s digitalization of the buying and selling process is the answer we’ve

Small biotech companies such as Denmark’s Orphazyme (NASDAQ:ORPH) usually have one major product, which pushes them into the spotlight. For ORPH stock, that one product is Arimoclomol. Source: Iryna Imago / Shutterstock.com Arimoclomol is a drug that could treat the rare progressive genetic disorder called Niemann-Pick Disease Type C (NPC). Investors looking for a breakthrough

Compared to the gigantic valuation of Churchill Capital Corp IV (NYSE:CCIV) stock, the performance of Lucid Motors — with whom Churchill is expected to merge next week — remains subpar. Source: gg5795 / Shutterstock.com Meanwhile, CCIV stock has been badly hurt by the retreat of meme stocks in the last month, and I expect that trend

The timing of DiDi Global’s (NYSE:DIDI) initial public offering could not have been any better. Insiders and early investors probably knew about the Chinese regulatory crackdown days after its IPO. They lost the least after DIDI stock plunged. Speculators who bought the stock are in for a rough ride next. Source: Piotr Swat / Shutterstock.com

The Airbnb (NASDAQ:ABNB) story is well recognized among investors today as the company that invented a travel and lodging category that did not formally exist before. ABNB stock has had a storied time since the company went public. Source: AlesiaKan / Shutterstock.com Airbnb is a so-called two-sided online marketplace (meaning both hosts and guests are

I first invested in Alibaba (NYSE:BABA) stock back in late 2015 at a price of $68 per share. Source: Nopparat Khokthong / Shutterstock.com At the time, my thesis was extremely simple. E-commerce is the future of retail. Amazon (NASDAQ:AMZN) is the e-commerce leader in the U.S. market. AMZN stock has been an incredible long-term investment.

For a few weeks, Reddit’s r/WallStreetBets kept the buying pressure strong on AMC Entertainment (NYSE:AMC) stock. But when the Nasdaq started to lose momentum late last week, AMC stock started to lose its hold on the $60 level. Source: QualityHD / Shutterstock.com Short interest, an indicator of bearishness, is at 16.6%. The more shares fall,

The most famous expression in advertising is probably, “Advertisers go where the eyeballs are.” The evidence suggests that this principle remains as true in 2021 as it was in 2001, 1981 and 1961. And that’s bad news for the owners of Skillz (NYSE:SKLZ) stock. Source: NYCStock / Shutterstock.com That’s because Skillz, a platform that enables

Nio (NYSE:NIO) has had one of the most incredible turnarounds in recent memory. The company’s initial public offering (IPO) was priced at $6 per share, and NIO stock stayed in the single digits following the IPO. Source: Sundry Photography / Shutterstock.com While Nio made a decent case about being able to beat Tesla (NASDAQ:TSLA) in